CHU F.Bourguiba
Monastir, 5000, Tunisia
NCT Number: NCT04982341
The investigators evaluate the effects of High-flow nasal cannula (HFNC) in association with prone in patients with Covid-19 severe ARF.
Looking for future studies?
Notify MeAll sexes
Observational
Monastir, 5000, Tunisia
The investigators evaluate the effects of High-flow nasal cannula (HFNC) in association with prone in patients with Covid-19 severe ARF.
All patients with ARF related to Covid-19 and admitted to the ICU are turned in prone position whenever tolerated, while receiving oxygenation with HFNC.
Outcomes of interest are the rate of success or failure (defined as the need for intubation and mechanical ventilation)
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
patients are returned from prone to supine position while receiving oxygenation through HFNC
Time frame: through study completion, an average of 28 days
successful oxygenation without intubation
Hôpital Universitaire Fattouma Bourguiba
Other
Effectiveness of High-flow Nasal Cannula and Prone Positioning in Awake Patients With COVID-19 and Severe Acute Respiratory Failure
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04402879
ARDS, Acute Respiratory Distress Syndrome
Calgary, Alberta, Canada
View Trial DetailsNCT04468126
Acute Respiratory Failure, Hypoxemic Respiratory Failure
Poitiers, France
View Trial DetailsNCT02951130
Congenital Abnormalities, Congenital Diaphragmatic Hernia
Birmingham, Alabama, United States
View Trial DetailsNCT07121257
ARDS, Hypoxemic Respiratory Failure
Barcelona, Spain
View Trial Details